截至2025年6月，植物医生在全球已开设4269家线下门店，如今门店覆盖中国、日本、印尼、泰国等多 个市场。这一密集的零售网络不仅为公司带来稳健的营收基础，更通过面对面服务增强了用户黏性与品 牌体验。公司已连续多年位列中国单品牌化妆品店零售额榜首，线下渠道优势显著。植物医生不仅输出 产品，更通过本土化运营传递"高山植物"的东方护肤哲学，其"全球领先的单品牌护肤品专卖店"认证也 进一步强化了国际市场的专业形象。 截至2025年10月，植物医生已累计获得223项专利，其中发明专利68项，并完成了齿瓣石斛茎提取物等 新原料备案。这种"研发-专利-原料-产品"的闭环能力，使公司能够持续将高山植物资源转化为具有市场 竞争力的护肤成分，不断强化"中国成分"的科技内涵。 前不久，深圳证券交易所官网更新了植物医生（DR PLANT）的IPO项目动态，正式向A股主板发起冲 刺，标志着企业资本化进程的关键一步。 植物医生自创立以来，始终聚焦"高山植物，纯净美肌"的战略定位，围绕"中国品牌、中国成分"打造差 异化优势。这一清晰定位使其在竞争激烈的化妆品市场中形成了鲜明的品牌辨识度，为持续增长奠定了 品牌基础。 品牌的核心竞争力建立 ...

Core Insights - The company, Plant Doctor, is accelerating its IPO amidst intensifying competition in the Chinese cosmetics industry, focusing on high-altitude plant skincare as its niche market [1] - The brand's positioning of "high-altitude plants, pure beauty" aligns with consumer demand for natural, safe, and effective skincare ingredients, establishing a unique competitive advantage [1] Financial Performance - From 2021 to the first half of 2024, the company's revenue has consistently exceeded 2.1 billion yuan, with net profit increasing from 158 million yuan to 243 million yuan in 2023, reflecting a compound annual growth rate of 24% from 2022 to 2024 [2] - The net profit scale significantly surpasses the median level of industry peers, indicating strong profitability and industry representation [2] Channel Strategy - The company has developed a multi-channel strategy, with a focus on offline single-brand stores and an extensive online presence, achieving 4,269 offline stores by June 2025 [2] - The offline network not only generates substantial sales revenue but also serves as a brand image showcase and customer experience center, enhancing customer loyalty [2] Online Growth - Online channels act as a growth engine, with deep operations on platforms like Tmall and Douyin, and the introduction of the "Little Plant City" new retail model, which effectively channels offline traffic to online private domains [3] - This integration of online and offline sales has positioned the company as the top single-brand cosmetics store in China [3] R&D Investment - The company has invested nearly 250 million yuan in R&D during the reporting period, establishing a comprehensive research framework that includes basic plant research, formula development, and clinical testing across multiple locations [3] - As of October 2025, the company has secured 223 patents, ensuring continuous product innovation and rapid market responsiveness [3] Future Strategy - The IPO proceeds will be allocated to brand marketing, upgrading the R&D center, technological transformation of production bases, and information system development, outlining a clear strategic path for future growth [3] - By leveraging its focus on high-altitude plants, ongoing R&D, differentiated channel strategies, and clear brand positioning, the company aims to establish a competitive moat in the skincare market [3]

Core Viewpoint - The company, Plant Doctor, has officially initiated its IPO process for listing on the A-share main board, focusing on high-altitude plant skincare products and emphasizing its brand strategy of "high-altitude plants, pure beauty" [1] Group 1: R&D and Product Development - Plant Doctor has established a deep collaboration with the Kunming Institute of Botany, forming the "Plant Doctor R&D Center," which includes a unique research structure of "one center and five bases" [3] - The R&D framework covers raw material research, formula development, production processes, and quality assurance, with significant breakthroughs in the field of Dendrobium orchid active ingredients [3] - The company has developed a product matrix that includes various series such as "Dendrobium Orchid Firming and Smoothing" and "Snow Lotus Soothing Care," covering multiple product categories [5] Group 2: Business Model and Market Position - Plant Doctor employs an online and offline strategy, with over 4,200 offline chain stores by June 2025, providing unique product experiences and emotional value to consumers [7] - According to a report by the China Fragrance and Cosmetic Industry Association, Plant Doctor ranks first among single-brand cosmetic stores in China based on projected retail sales for 2024 [7] Group 3: International Expansion and Recognition - The company has made substantial progress in its international strategy, with store networks covering multiple countries, including Thailand, where it opened a flagship store in November 2025 [7] - Plant Doctor has been recognized as a "global leading single-brand skincare specialty store" by Euromonitor International for three consecutive years, reflecting its strong market position [9] Group 4: Brand Philosophy and Future Outlook - The brand philosophy is rooted in traditional Chinese culture, integrating the wisdom of Naxi herbal medicine with modern biotechnology, aiming to provide consumers with a pure skincare experience from high-altitude plants [9] - With the advancement of its IPO process, Plant Doctor is expected to leverage capital market resources to strengthen its leading position in high-altitude plant skincare and accelerate its international expansion [9]

Core Viewpoint - Beijing Plant Doctor Cosmetics Co., Ltd. is set to go public on the Shenzhen Stock Exchange, showcasing its strong brand power built over 30 years through strategic focus, research, and market expansion [1] Group 1: Company Overview - The Plant Doctor brand was established in 1994 and has focused on the "highland plant skincare" sector, successfully creating iconic product lines such as "Dendrobium," "Purple Ganoderma," and "Cordyceps" [1] - The company has achieved stable revenue growth and continuous profit increase even during challenging industry periods from 2022 to 2024, demonstrating resilience through long-term dedication [1] Group 2: Research and Development - The company has a long-term partnership with the Kunming Institute of Botany, signing a 20-year strategic cooperation agreement in 2014, which has led to significant advancements in research [2] - A key achievement includes the extraction of high-activity Dendrobium oligosaccharides, which has been validated for its effectiveness in promoting collagen production, breaking the monopoly of international brands on high-end skincare ingredients [2] Group 3: Brand Philosophy and Social Responsibility - The brand embodies the philosophy of "respecting nature, valuing science, and giving back to society," collaborating with the UN Development Programme since 2021 on biodiversity and highland plant protection initiatives [3] - Initiatives include the establishment of a biodiversity experience garden and the "Wu Zhengyi Botany Award" to encourage scientific innovation, transforming short-term commercial actions into long-term value investments [3] - The brand's growth strategy integrates ecological protection and social responsibility, enhancing its brand value system and ensuring sustainable development [3]

Core Viewpoint - DR PLANT, a Chinese cosmetics brand known for its "high mountain plants, pure skin," is set to go public on the Shenzhen Stock Exchange, marking a new phase of capital empowerment for the company [1] Offline Channel as a "Moat" - As of June 2025, DR PLANT has established 4,269 offline stores across various markets, including Japan, Indonesia, Thailand, and Hong Kong, demonstrating its scale advantage and deep understanding of offline channels [2] - The offline stores serve not just as sales points but as core areas for brand experience, user service, and emotional connection, enhancing customer loyalty and word-of-mouth [2] - The brand has ranked second in the beauty and body care sector of the "Top 100 Chain Enterprises in the Service Industry" for two consecutive years and is the top single-brand cosmetics store in China based on 2024 multi-channel retail revenue [2] Research and Innovation Driving Product Strength - Research and innovation are central to DR PLANT's strategy, with a focus on "high mountain plants" and collaboration with authoritative institutions like the Kunming Institute of Botany [3] - The company has established a research framework consisting of one center and five bases, covering all aspects of research and development [3] - As of October 31, 2025, DR PLANT has obtained 223 patents, including 68 invention patents, showcasing its strong R&D capabilities [3] Comprehensive Product Matrix - DR PLANT has successfully launched multiple product lines, including Dendrobium, Centella Asiatica, and others, covering skincare, makeup, and body care, creating a complete product matrix [4] Brand Culture and Social Responsibility - The brand is influenced by the wisdom of the Naxi ethnic group's herbal medicine, integrating respect for nature, scientific principles, and social responsibility into its core values [5] - DR PLANT actively engages in biodiversity protection and promotes the cultural concept of harmony between humans and nature [5] - The brand has been recognized as a "global leader in single-brand skincare stores" for three consecutive years, highlighting its leading position in the global single-brand store market [5] International Expansion - DR PLANT is steadily advancing its international presence, with a flagship store opening in Bangkok, Thailand, marking its entry into the fourth overseas market [6] - The brand aims to promote the vision of "the world loving Chinese cosmetics" through product offerings, store designs, and cultural exports [6] - The IPO process is seen as a milestone for the company and a potential turning point for the Chinese cosmetics industry, shifting from a marketing-driven approach to a dual-driven model of technology and brand [6]

Core Insights - The skincare industry in China is expanding rapidly, driven by increasing consumer demand for safety and efficacy in product ingredients, making product quality a key competitive barrier [1] - Plant Doctor is set to launch an IPO on the Shenzhen Stock Exchange in November 2025, aiming to raise 999.8 million yuan by issuing up to 26.67 million shares, marking a significant step for the brand after 30 years in the high-altitude plant skincare market [1] Company Research - Plant Doctor focuses on the unique skincare needs of East Asian consumers, developing products that address common issues such as hydration, anti-aging, and sensitivity through a comprehensive R&D framework [3] - The brand has established a collaborative R&D center with the Kunming Institute of Botany, focusing on the active ingredients derived from high-altitude plants, supported by five additional research bases [3] - The company has achieved significant breakthroughs, including a patented technology for extracting small-molecule components from Dendrobium, which has led to the creation of a star product series that has garnered widespread consumer recognition [5][6] - As of October 2025, Plant Doctor holds a total of 223 patents, including 68 invention patents, reinforcing its competitive edge in the Eastern skincare market [6] Quality Control and Production - Product quality is a cornerstone of Plant Doctor's valuation and development, with a strict selection of high-altitude plant materials and a state-of-the-art production facility in Guangdong [8] - The company has invested in a 38,000 square meter factory to enhance its R&D, manufacturing, storage, and logistics capabilities, with 109 million yuan from the IPO earmarked for technological upgrades [8] - A rigorous three-tier testing system exceeding national standards ensures that every product batch undergoes safety, stability, and efficacy evaluations, minimizing quality risks [8] Future Outlook - The IPO will serve as a catalyst for Plant Doctor to intensify its research on high-altitude plants and new product development, while optimizing its integrated online and offline retail strategy [10] - The company aims to increase market penetration of its core product matrix and work towards its vision of making Chinese cosmetics globally loved, contributing to the high-quality development of domestic beauty brands [10]

Core Insights - The skincare and cosmetics market in China is rapidly growing, becoming the second largest globally, with significant potential for future growth due to increasing consumer spending and beauty care habits [1][12] - Beijing Plant Doctor Cosmetics Co., Ltd. is preparing for an IPO, focusing on high-altitude plant skincare products, with projected revenue exceeding 2.1 billion yuan in 2024 [1][20] Industry Overview - The cosmetics industry is segmented into various categories, with skincare products accounting for 50.49% of the total market, projected to reach 271.2 billion yuan in 2024 [4] - The market is characterized by intense competition, with both international brands like L'Oréal and domestic brands like Proya and Pechoin vying for market share [12][17] Company Profile - Plant Doctor specializes in skincare, offering products derived from high-altitude plants, with a diverse product range including creams, serums, and masks [4][5] - The company has established a research center in collaboration with the Kunming Institute of Botany and has multiple R&D bases across China and Japan [5] Financial Performance - Plant Doctor's revenue has shown slow growth, with figures of approximately 2.12 billion yuan in 2022, 2.15 billion yuan in 2023, and 2.16 billion yuan in 2024 [14] - The company's gross profit margin has fluctuated, with rates of 55.22% in 2022, 60.34% in 2023, and 58.9% in 2024, which is lower than some competitors [14][15] Sales and Distribution - The company employs a mixed sales model, with 64% of revenue from distribution and 36% from direct sales, indicating a reliance on distributors [6][10] - Despite the growth of e-commerce in the cosmetics sector, Plant Doctor still derives over 70% of its revenue from offline sales [10] Management and Ownership - The company was founded in 2016 and has undergone structural changes, with key management holding significant shares and control over the company [21][22] - Recent cash dividends have primarily benefited major shareholders, raising questions about the allocation of funds [22] Future Outlook - The IPO aims to raise approximately 999.8 million yuan for marketing, brand development, and production upgrades, indicating a strategic focus on enhancing market presence and operational efficiency [20]

Core Viewpoint - The company "Plant Doctor" is preparing for an IPO, aiming to raise approximately 998 million yuan by issuing up to 26.67 million shares, with over 53% of the funds allocated for marketing and brand development [1]. Financial Performance - Plant Doctor's revenue has stagnated, with reported revenues of 2.117 billion yuan, 2.151 billion yuan, and 2.156 billion yuan from 2022 to 2024, while net profits were 168 million yuan, 229 million yuan, and 242 million yuan, showing a decline in growth rate from 36.3% in 2023 to 5.7% in 2024 [6]. - By mid-2025, the company achieved revenue of 960 million yuan, less than half of the total revenue for 2024, with a net profit of 79 million yuan, only 32.6% of the previous year's total [6]. - Despite declining revenue and profits, the company increased cash dividends to 80% of the total for 2024 in the first half of 2025, amounting to 80 million yuan [6]. Product and Production Insights - The production capacity utilization rates for core products indicate stagnation, with the utilization for water and cream products at 95.26% and essence products at 87.52% as of mid-2025 [7]. - The mask products achieved a record high capacity utilization of 108.15%, but the sales rate was only 65.27%, marking a new low [7]. Marketing and R&D Expenditure - The company has significantly increased marketing expenditures, spending 743 million yuan in 2024, which accounted for 34.47% of revenue, and 3.65 billion yuan in the first half of 2025, rising to 38% of revenue [11][12]. - In contrast, R&D spending has decreased, with expenditures of 73.77 million yuan, 75.88 million yuan, and 66.33 million yuan from 2022 to 2024, representing only 3.08% of revenue in 2024 [12]. - The number of R&D personnel has decreased by nearly 50, from 166 in 2022 to 117 in mid-2025, with a low proportion of advanced degrees among staff [13][14]. Franchise and Compliance Issues - The company has expanded its franchise model to 4,269 stores, with 3,787 authorized stores and 482 direct stores, but this model has led to compliance issues and complaints [17][19]. - There have been 394 complaints regarding product safety and marketing practices, highlighting significant internal control deficiencies, particularly in franchise management [16][18]. - The company has faced regulatory scrutiny, with multiple instances of non-compliance regarding product safety and marketing practices, including the sale of banned substances and unlicensed operations [24][25].

Core Viewpoint - The IPO application of Beijing Plant Doctor Cosmetics Co., Ltd. has been suspended due to outdated financial data, which poses challenges for its ambition to become the first listed single-brand cosmetics store in China [4][3]. Company Overview - Beijing Plant Doctor was established in 1994 and has over 30 years of experience in the cosmetics industry, focusing on skincare products since 2004 [8]. - The company aims to raise approximately 998 million yuan through its IPO, with plans to invest in marketing, brand building, headquarters and R&D center construction, information system upgrades, and production base technology transformation [6]. Financial Performance - The company's revenue has shown steady growth, with projected revenues of 2.12 billion yuan, 2.15 billion yuan, and 2.16 billion yuan for 2022, 2023, and 2024 respectively, and net profits of 170 million yuan, 230 million yuan, and 240 million yuan for the same years [8]. - The revenue composition is primarily from core products such as lotions, creams, serums, and masks, which account for over 99% of total revenue [9]. Market Position - According to Euromonitor data, Plant Doctor ranks 8th among domestic brands in the Chinese cosmetics market and 7th in the skincare segment for 2024 [8]. - If the IPO is successful, the company will have over 4,000 offline stores, solidifying its position as the first single-brand cosmetics stock in China [7]. Competitive Landscape - The Chinese cosmetics market is characterized by a concentration of leading brands, with L'Oréal, Procter & Gamble, and Estée Lauder holding significant market shares of 14.4%, 7.9%, and 5.1% respectively [14]. - Plant Doctor's market share is relatively small at 0.8%, with local competitors like Proya, Naturals, and Pechoin holding a combined market share of 6.3% [14]. Sales Channel Strategy - The company has a significant number of offline stores, totaling 4,328 by the end of 2024, which is much higher than its competitors [15]. - The sales revenue from offline channels accounts for 70-80% of total sales, while online sales contribute around 20% [16]. Profitability Challenges - The reliance on offline sales has led to higher rental liabilities and financial expenses, resulting in a financial expense ratio that exceeds that of competitors [17]. - The company primarily uses a distribution model, with 64% of revenue coming from distributors, which has lower profit margins compared to direct sales [17][18]. R&D and Management - The company has invested in R&D, with expenses of 73.77 million yuan, 75.88 million yuan, and 66.33 million yuan from 2022 to 2024, representing 3.48%, 3.53%, and 3.08% of revenue respectively [25]. - Future plans include increasing R&D investment and optimizing management platforms, although the recent IPO suspension adds uncertainty to these goals [28].

Group 1: Industry Overview - The Z generation is increasingly dominating the consumer market, shifting the beauty industry from a simple consumption slogan to a core driving force for upgrades [1] - The Chinese cosmetics market is facing a slowdown in growth, with retail sales expected to reach 435.7 billion yuan in 2024, a year-on-year decline of 1.1% [1] - Despite overall market pressure, domestic beauty brands are showing resilience, with notable performance from brands like Plant Doctor, which is advancing its IPO process [1] Group 2: Company Profile - Plant Doctor has been focused on high-altitude plant skincare products since its establishment in 1994, emphasizing a single brand strategy [2] - The company has built a comprehensive product matrix, including various series such as "Dendrobium" and "Centella Asiatica," covering multiple product categories [2] - Plant Doctor's revenue has steadily increased from 2.12 billion yuan in 2022 to 2.16 billion yuan in 2024, while net profit has grown from 158 million yuan to 243 million yuan, achieving a compound annual growth rate of 24% [2] Group 3: Market Position and Strategy - Plant Doctor has a strong offline presence with 4,328 stores, enhancing consumer experience and brand influence [3] - The company has received recognition as a "global leader in single-brand skincare specialty stores" from Euromonitor [3] - Plant Doctor is expanding into instant retail, leveraging its offline store network to provide convenient shopping experiences through platforms like Meituan and JD [3] - The ongoing IPO process aims to position Plant Doctor as the first single-brand beauty stock in A-shares, supported by its unique brand positioning and robust performance [3]